Skip to main content
Michael Snyderman, MD, Oncology, Buffalo, NY, Mercy Hospital

MichaelC.SnydermanMD

Oncology • Buffalo, NY

Asst. Prof SUNY at Buffalo, Asst. Prof Oncology, Adjunct Faculty, Roswell Park Cancer Institute, Founder and President of Research Institute for Viral Oncology (RivoResearch)

Join to view full profile

Dr. Snyderman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Snyderman's full profile

Already have an account?

Summary

  • I am the Founder and President of the nonprofit Research Institute for Viral Oncology (RIVO.org). Why study viruses and cancer? The reason is that there are 23 articles published in peer reviewed, scientific and medical journals that show that antiviral drugs can improve outcomes in cancer, sometimes dramatically. RIVO’s first goal was to support research to prove the infection of cancer by cancer viruses. The same techniques that were used to sequence the human genome were employed and the usual analysis was made more in keeping with the biological events. We analyzed both the DNA and RNA of the tumor and enriched viral sequences. Looking at common cancers: colorectal and lung, viruses were present, the viruses known to commonly infect us. Presumably, most people keep these viruses confined to a few cells or "reservoir" but patients with cancer can't. We plan to study many more cancers. RIVO’s second goal is to support the development of antiviral drug treatments of cancer. Antiviral drugs are currently available that can effectively treat any of the 14 known cancer viruses. Treating the cancer virus could reverse many of the viral-induced changes that drive the malignancy and that protect the cancer from being attacked by the immune system. This could mean that adding antiviral drugs to standard management could improve efficacy. Improved efficacy could allow less intense standard therapy and therefore lower toxicity.

Education & Training

  • University at Buffalo
    University at BuffaloResidency, Internal Medicine, 1973 - 1975
  • Temple University Hospital
    Temple University HospitalFellowship, Hematology and Medical Oncology, 1970 - 1971
  • Temple University Hospital
    Temple University HospitalResidency, Internal Medicine, 1967 - 1970
  • Lewis Katz School of Medicine at Temple University
    Lewis Katz School of Medicine at Temple UniversityClass of 1967
  • Temple University
    Temple UniversityA.B., Biology, 1963

Certifications & Licensure

  • NY State Medical License
    NY State Medical License Active through 2024
  • NY State Medical License
    NY State Medical License 1973 - 2024
  • PA State Medical License
    PA State Medical License Active through 1976
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Love Award “for Outstanding Service” Mercy Hospital of Buffalo, NY, 2012
  • Best Teaching Attending Mercy Hospital/SUNY Buffalo Internal Medicine Residents, 1983, 1990, 1995

Publications & Presentations

PubMed

Abstracts/Posters

  • Snyderman M, Mikovits JA, ASCO Proceedings, 1/1/2013
  • Mikovits A, Snyderman M, ASCO Proceedings, 1/1/2013
  • Snyderman M, Hematological Malignancies Houston 2010 (MD Anderson Cancer Center), 10/1/2010
  • Join now to see all

Lectures

  •  
    Medical Grand Rounds; Mercy Hospital of Buffalo, NY - 1/1/2010
  •  
    Mercy Hospita Annual John J. O’Brien, M.D. Research Symposium - 1/1/2006
  •  
    Mercy Hospita Annual John J. O’Brien, M.D. Research Symposium - 1/1/2002
  • Join now to see all

Hospital Affiliations

Dr. Michael Snyderman, Dr. Michael Snyderman, MD, Dr. M Snyderman, Dr. Michael C. Snyderman